Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
elagolix + estradiol + norethindrone acetate
- Development stage
- Approved
- Lead developer
- AbbVie
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Oriahnn is an FDA-approved oral fixed-dose combination prescription drug developed by AbbVie in collaboration with Neurocrine Biosciences. It is indicated for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women. The combination consists of elagolix (a small-molecule gonadotropin-releasing hormone [GnRH] receptor antagonist), estradiol (an estrogen), and norethindrone acetate (a progestin). Elagolix suppresses ovarian hormone production by antagonizing the GnRH receptor, while the estradiol and norethindrone acetate components serve as 'add-back' therapy to mitigate hypoestrogenic side effects, such as bone mineral density loss and vasomotor symptoms. Due to the risk of irreversible bone loss, treatment with Oriahnn is limited to a maximum duration of 24 months.
- Brand names
- Oriahnn
- Other names
- elagolix/estradiol/norethindrone acetateelagolix, estradiol, and norethindrone acetateelagolix sodium + estradiol + norethindrone acetate
02
Targets
ESR1 (ERα)GnRHR (Gonadotropin-releasing hormone receptor)PR (Progesterone receptor)
Beyond the preview
Go deeper on elagolix + estradiol + norethindrone acetate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on elagolix + estradiol + norethindrone acetate.